Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Prognosis
359 results:
1. Cost-effectiveness analysis of tislelizumab vs. camrelizumab for the treatment of second-line locally advanced or metastatic esophageal squamous cell carcinoma.
Chen P; Fu C; Shen L; Fei Z; Luo M; Chen Y; Li H
BMC Health Serv Res; 2024 May; 24(1):676. PubMed ID: 38807104
[TBL] [Abstract] [Full Text] [Related]
2. The effect of liver metastases on clinical efficacy of first-line programmed death-1 inhibitor plus chemotherapy in esophageal squamous cell carcinoma: A post hoc analysis of ASTRUM-007 and meta-analysis.
Gao J; Song Y; Kou X; Tan Z; Zhang S; Sun M; Zhou J; Fan M; Zhang M; Song Y; Li S; Yuan Y; Zhuang W; Zhang J; Zhang L; Jiang H; Gu K; Ye H; Ke Y; Qi X; Wang Q; Zhu J; Huang J
Cancer Med; 2024 May; 13(10):e7203. PubMed ID: 38769930
[TBL] [Abstract] [Full Text] [Related]
3. Dynamic radiological features predict pathological response after neoadjuvant immunochemotherapy in esophageal squamous cell carcinoma.
Ruan Y; Ma Y; Ma M; Liu C; Su D; Guan X; Yang R; Wang H; Li T; Zhou Y; Ma J; Zhang Y
J Transl Med; 2024 May; 22(1):471. PubMed ID: 38762454
[TBL] [Abstract] [Full Text] [Related]
4. A nomogram based on the SII3 and clinical indicators predicts survival in patients with nasopharyngeal carcinoma treated with pd-1 inhibitors.
Chen X; Liang W; Wu X; Wang Y; Hong Y; Xie M; Han R; Lin Z
Medicine (Baltimore); 2024 May; 103(19):e38017. PubMed ID: 38728499
[TBL] [Abstract] [Full Text] [Related]
5. Spatiotemporal characteristics of tissue derived small extracellular vesicles is associated with tumor relapse and anti-pd-1 response.
Fu QY; Xiong XP; Xia HF; Liu XC; Yu ZL; Liu KW; Zeng J; Sun YF; Jia J; Chen G
Cancer Lett; 2024 Jun; 591():216897. PubMed ID: 38631664
[TBL] [Abstract] [Full Text] [Related]
6. [Phase Ⅱ clinical trial of pd-1 inhibitor combined with chemotherapy for locally advanced resectable oral squamous cell carcinoma].
Wang HL; Yue K; Wu YS; Duan YS; Jing C; Wang XD
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2024 Apr; 59(4):335-342. PubMed ID: 38599641
[No Abstract] [Full Text] [Related]
7. STING agonist inflames the cervical cancer immune microenvironment and overcomes anti-pd-1 therapy resistance.
Li T; Zhang W; Niu M; Wu Y; Deng X; Zhou J
Front Immunol; 2024; 15():1342647. PubMed ID: 38550593
[TBL] [Abstract] [Full Text] [Related]
8. RNA splicing regulator EIF3D regulates the tumor microenvironment through immunogene-related alternative splicing in head and neck squamous cell carcinoma.
Lu D; Mihoayi M; Ablikim Y; Arikin A
Aging (Albany NY); 2024 Mar; 16(7):5929-5948. PubMed ID: 38535990
[TBL] [Abstract] [Full Text] [Related]
9. M6A-mediated molecular patterns and tumor microenvironment infiltration characterization in nasopharyngeal carcinoma.
Wang Y; Peng L; Wang F
Cancer Biol Ther; 2024 Dec; 25(1):2333590. PubMed ID: 38532632
[TBL] [Abstract] [Full Text] [Related]
10. Treatments on the horizon for locally advanced basal cell carcinoma.
Idriss MH; Stull CM; Migden MR
Cancer Lett; 2024 May; 589():216821. PubMed ID: 38521198
[TBL] [Abstract] [Full Text] [Related]
11. Identification of Metabolism-Related Prognostic Biomarkers and Immune Features of head and neck Squamous Cell Carcinoma.
Zhou R; Wang J
Crit Rev Immunol; 2024; 44(4):61-78. PubMed ID: 38505922
[TBL] [Abstract] [Full Text] [Related]
12. Tyrosine phosphatase
Chen X; Keller SJ; Hafner P; Alrawashdeh AY; Avery TY; Norona J; Zhou J; Ruess DA
Front Immunol; 2024; 15():1340726. PubMed ID: 38504984
[TBL] [Abstract] [Full Text] [Related]
13. Immune checkpoint CD161/LLT1-associated immunological landscape and diagnostic value in oral squamous cell carcinoma.
Hu X; Dong Y; Xie S; Song Y; Yu C; He Y; Wang Z; Hu Q; Ni Y; Ding L
J Pathol Clin Res; 2024 Mar; 10(2):e353. PubMed ID: 38502058
[TBL] [Abstract] [Full Text] [Related]
14. Intratumor tertiary lymphatic structure evaluation predicts the prognosis and immunotherapy response of patients with colorectal cancer.
Feng H; Zhang S; Zhou Q; Han F; Du G; Wang L; Yang X; Zhang X; Yu W; Wei F; Hao X; Ren X; Zhao H
Front Immunol; 2024; 15():1302903. PubMed ID: 38500886
[TBL] [Abstract] [Full Text] [Related]
15. A distinct tumor microenvironment makes anaplastic thyroid cancer more lethal but immunotherapy sensitive than papillary thyroid cancer.
Han PZ; Ye WD; Yu PC; Tan LC; Shi X; Chen XF; He C; Hu JQ; Wei WJ; Lu ZW; Qu N; Wang Y; Ji QH; Ji DM; Wang YL
JCI Insight; 2024 Mar; 9(8):. PubMed ID: 38478516
[TBL] [Abstract] [Full Text] [Related]
16. Chronic Lymphocytic Thyroiditis with Oncocytic Metaplasia Influences PD-L1 Expression in Papillary Thyroid Carcinoma.
Santana VB; Krüger VM; Abrahão MCY; Cantú PLM; Brackmann RL; Pandolfi GM; Marisco LS; Remonatto G; Ferreira LA; Graudenz MS
Head Neck Pathol; 2024 Mar; 18(1):14. PubMed ID: 38457034
[TBL] [Abstract] [Full Text] [Related]
17. Perioperative immunotherapy for esophageal squamous cell carcinoma.
Wei DD; Fang JM; Wang HZ; Chen J; Kong S; Jiang YY; Jiang Y
Front Immunol; 2024; 15():1330785. PubMed ID: 38440724
[TBL] [Abstract] [Full Text] [Related]
18. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
[TBL] [Abstract] [Full Text] [Related]
19. Clinical significance of integrin αV and β superfamily members and focal adhesion kinase activity in oral squamous cell carcinoma: a retrospective observational study.
Sakurai S; Ishida Y; Shintani T; Yamasaki S; Matsui K; Hamana T; Nobumoto T; Yanamoto S; Hayashido Y
Pathol Oncol Res; 2024; 30():1611571. PubMed ID: 38312516
[No Abstract] [Full Text] [Related]
20. Characteristics and immune checkpoint status of radioiodine-refractory recurrent papillary thyroid carcinomas from Ukrainian Chornobyl Tissue Bank donors.
Bogdanova T; Rogounovitch TI; Zurnadzhy L; Mitsutake N; Tronko M; Ito M; Bolgov M; Chernyshov S; Gulevatyi S; Masiuk S; Yamashita S; Saenko VA
Front Endocrinol (Lausanne); 2023; 14():1343848. PubMed ID: 38260161
[TBL] [Abstract] [Full Text] [Related]
[Next]
